Regulatory actions for Nov. 24, 2025 Nov. 24, 2025 Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Sangamo.Read More
Other news to note for Nov. 24, 2025 Nov. 24, 2025 Biopharma happenings, including deals and partnerships, and other news in brief: Actimed, Anaptysbio, GSK, Lava, Tesaro, Xoma.Read More
In the clinic for Nov. 24, 2025 Nov. 24, 2025 Clinical updates, including data readouts and publications: Blue Lake, Contineum.Read More
Financings for Nov. 24, 2025 Nov. 24, 2025 Biopharmas raising money in public or private financings, including: Bioatla, Inhibikase.Read More
Appointments and advancements for Nov. 24, 2025 Nov. 24, 2025 New hires and promotions in the biopharma industry, including: Edgewise, Novabridge, Visara, Vivac.Read More
New Samyang Holdings, Samsung Biologics spin-offs debut on Kospi Nov. 24, 2025 By Marian (YoonJee) Chu No Comments Two South Korean conglomerates – Samyang Holdings Corp. and Samsung Biologics Co. Ltd. – listed their newly spun-off biopharmaceutical units on Korea Exchange’s (KRX) main trading board Nov. 24.Read More
Novo’s semaglutide fails in phase III Alzheimer’s trials Nov. 24, 2025 No Comments A preview of the next edition of BioWorld, Nov. 24, 2025Read More
Biggest gainers and losers for Nov. 17-21, 2025 Nov. 24, 2025 The top 10 biopharma stock gainers and losers for the week.Read More
Biopharma money raised: Jan. 1-Nov. 20, 2025 Nov. 21, 2025 Year-to-date money raised in public, private and other financings of biopharma companies.Read More
RSS
